Veterinary Practice News • Veterinary Practice News Canada • VetMedTeam • VetCE • Veterinary Professionals' NextGen

ACCOUNT SETTINGS
LOG OUT

Sign up for our weekly newsletter

News
Practice Management
Cat/Dog
Medicine
Brain Teaser
Education
MORE

Equine/Large Animal
Avian/Exotic
Videos
Get the Magazine
Classifieds
Products
- Demo-Casts
- Product Profiles
Events
Archives
- Digital Editions
- Newsletters
Digital Editions
Newsletters
E-book

#canine parvovirus

Parvo preventative picks up speed

December 29, 2020

Elanco Animal Health is set to acquire the global rights to Kindred Biosciences’ proprietary KIND-030, a monoclonal antibody being developed for the treatment and prevention of canine parvovirus.

SPONSORED CONTENT

Now, Simparica Trio™ simplifies protection

Simparica Trio (sarolaner/moxidectin/pyrantel) Chewables provide the critical protection dogs need all in one simple-to-give monthly chewable.

Preventative for deadly puppy disease may be imminent

September 18, 2020

An efficacy study of a monoclonal antibody targeting canine parvovirus has shown complete efficacy in its prevention, its maker says.

Canine parvovirus treatment may be in the works

August 19, 2019

Veterinarians may soon have access to an antibody effective in the treatment of canine parvovirus (CPV).

New on

Join VPN Plus+ today to get access to exclusive content like:

Compassion without the fatigue

Video: Tips to working with clients who have mental health conditions

We finally learn…what’s in the box!

A new way to go green: mentor a recent graduate

COVID-19

Post-pandemic social media marketing: What do you need to know?

Reassure owners to prevent post-pandemic surrenders

Reduce pet-to-pet contact, shelters warned

Ready to reopen? How you see appointments will change

Animal respiratory, GI insurance claims remain consistent in face of COVID-19

Load More

About Us
About VPN Plus+
Contact Us
Advertise

Get the Magazine
Get our Newsletter

Privacy Policy
Terms of Use

FOLLOW US @VetPracticeNews
#VetPracticeNews

Copyright ©2021 Kenilworth Media Inc. All Rights Reserved.